Today’s Market Runner: Adamas Pharmaceuticals Inc Can’t Burn Your Long Portfolio. Has Another Strong Session

Today's Market Runner: Adamas Pharmaceuticals Inc Can't Burn Your Long Portfolio. Has Another Strong Session

The stock of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) is a huge mover today! About 165,634 shares traded hands or 9.40% up from the average. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has declined 25.00% since April 4, 2016 and is downtrending. It has underperformed by 26.09% the S&P500.
The move comes after 9 months positive chart setup for the $315.39M company. It was reported on Nov, 4 by Barchart.com. We have $31.18 PT which if reached, will make NASDAQ:ADMS worth $381.62M more.

Analysts await Adamas Pharmaceuticals Inc (NASDAQ:ADMS) to report earnings on November, 10. They expect $-0.81 EPS, 0.00% or $0.00 from last year’s $-0.81 per share. After $-0.78 actual EPS reported by Adamas Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 3.85% negative EPS growth.

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Ratings Coverage

Out of 7 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 6 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 86% are positive. Adamas Pharmaceuticals has been the topic of 12 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Mizuho maintained Adamas Pharmaceuticals Inc (NASDAQ:ADMS) rating on Thursday, May 12. Mizuho has “Neutral” rating and $16 price target. Credit Suisse maintained it with “Outperform” rating and $37 target price in Thursday, December 24 report. Mizuho initiated the stock with “Neutral” rating in Tuesday, January 19 report. The firm has “Buy” rating by Aegis Capital given on Tuesday, September 22. The firm has “Market Outperform” rating by JMP Securities given on Friday, April 1. Noble Financial initiated the stock with “Buy” rating in Friday, June 17 report. The rating was downgraded by TheStreet to “Sell” on Friday, October 16. Cowen & Co initiated it with “Outperform” rating and $45 target price in Tuesday, January 19 report. On Thursday, April 28 the stock rating was maintained by Mizuho with “Neutral”. The firm earned “Buy” rating on Thursday, September 8 by Mizuho.

According to Zacks Investment Research, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas.”

More important recent Adamas Pharmaceuticals Inc (NASDAQ:ADMS) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on June 21, 2011, also Fool.com published article titled: “Why Adamas Pharmaceuticals Dropped 25.3% in February”, Fool.com published: “Here’s Why Adamas Pharmaceuticals’ Stock Soared Today” on December 23, 2015. More interesting news about Adamas Pharmaceuticals Inc (NASDAQ:ADMS) was released by: Reuters.com and their article: “BRIEF-Adamas Pharmaceuticals files for mixed shelf of upto $200 mln” with publication date: November 03, 2016.

ADMS Company Profile

Adamas Pharmaceuticals, Inc., incorporated on November 15, 2000, is a pharmaceutical company. The Firm is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). The Firm is engaged in modifying the pharmacokinetic profiles of approved drugs to create therapeutics for use alone and in fixed-dose combination products. The Company’s segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The Firm has selected aminoadamantanes as its initial area of focus, which have the ability to modulate multiple neurotransmitter systems, which are the molecular pathways that control brain function.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment